Loading market dashboard
Cyxone AB (publ)
CYXO.STHealthcareSTOSE
Business DescriptionOpen for the full company profile when you need deeper context.
Business Description
Open for the full company profile when you need deeper context.
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Check out other names from the same Biotechnology industry as CYXO.ST.